Yang Rohr backs HB4327 to initiate audit of state’s 340B drug program entities

Rep. Janet Yang Rohr (D-41st) cast a Yes vote for HB4327, a bill authorizing an audit of entities in Illinois involved in the 340B Drug Discount Program, during the 104th General Assembly on May 31, 2026, the Illinois House noted. The legislation secured House passage with a 106-8 vote.

As detailed in the official bill text, the initiative is titled: "AUDITOR GENERAL-340B AUDIT."

The following summary interprets the primary provisions of the bill as written.

Essentially, the bill instructs the Illinois auditor general to, upon the law’s effective date, promptly launch a comprehensive audit of 340B covered entities within the state and their engagement in the federal 340B Drug Discount Program. The audit must review profits from 340B drug sales, expenditures on third-party administrators, payments to pharmacy benefit managers and contract pharmacies, contract pharmacy drug ownership structures, average markups on 340B-priced pharmaceuticals, and the rate at which patients in need receive these discounts at the point of sale. Findings and recommendations must be delivered to the General Assembly.

HB4327’s status was recorded as 'Senate Committee Amendment No. 1 House Concurs.'

Rohr earned her undergraduate degree from Northwestern University in 2002 and a graduate degree from University of Chicago Booth School of Business in 2010.

Rohr, a Democrat, began representing Illinois’s 41st House District in 2021 after succeeding former state representative Grant Wehrli.

Illinois legislation follows a multi-step legislative process spanning bill introduction in either chamber, committee review, debates on the floor, and votes in both legislative bodies before proceeding to the governor for approval or veto. The biennial legislative cycle typically results in thousands of introduced bills each session, although only a limited number proceed to become law.